Issue 171 Item 6 New Avandamet (Rosiglitazone Maleate/Metformin) Dosage Strength

New Dosage Strengths Offer Physicians and Patients Dosing Flexibility For Managing Type 2 Diabetes

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) approved new dosage strengths for Avandamet™ — a treatment that combines two diabetes medications in a convenient pill. The new Avandamet dosages of 1 gram metformin combined with 2 mg or 4 mg rosiglitazone will be available to patients in approximately six weeks.

"GlaxoSmithKline is pleased with the FDA’s approval of the new Avandamet 1 gram tablets as they will offer additional dosing flexibility for the many type 2 diabetes patients who are currently taking a total daily dose of 2 grams of metformin," said David Brand, Vice President, Metabolic/Endocrine Marketing, GlaxoSmithKline. "Over the long-term, many patients on traditional agents do not reach the American Diabetes Association (ADA) recommended goal for blood sugar control, which puts them at increased risk for diabetes-related complications such as heart disease. With Avandamet, we look to provide an effective and convenient treatment option for patients to help manage their type 2 diabetes."

Avandamet is currently available in three tablet strengths of rosiglitazone/metformin, respectively: 1 mg /500 mg, 2 mg/500 mg, 4 mg/500 mg. SOURCE: GlaxoSmithKline

===========================

Diachrome (chromium picolinate and biotin) Samples.
We have convinced the manufacturer “Nutrition 21” to supply you, our medical professional readers, with samples for personal or patient use. Click here to learn how to get them.